

500 Chipeta Way, Salt Lake City, Utah 84108-1221

phone: 801-583-2787, toll free: 800-522-2787

Jonathan R. Genzen, MD, PhD, Chief Medical Officer

Patient Age/Sex:

Unknown

Specimen Collected: 15-Dec-23 12:17**Infliximab/Ab to Infliximab Quantitation** | Received: 15-Dec-23 12:18 | Report/Verified: 15-Dec-23 12:20

Procedure	Result	Units	Reference Interval
Infliximab Quantitation	<0.5 ^L ⁱ¹	ug/mL	[>=0.5]
Antibodies to Infliximab Quantitation	160 ^H ⁱ²	ng/mL	[<=19]

Test Information

i1: Infliximab Quantitation

INTERPRETIVE INFORMATION: Infliximab Quantitation

Results of 0.5 ug/mL or higher indicate the detection of infliximab or an infliximab biosimilar. Therapeutic level may vary depending on the disease being treated.

i2: Antibodies to Infliximab Quantitation

INTERPRETIVE INFORMATION: Antibodies to Infliximab Quantitation

Results of 20 ng/mL or higher indicate the detection of antibodies against infliximab or an infliximab biosimilar. Interpret in the context of infliximab or infliximab biosimilar trough concentration to determine clinical significance and impact on treatment efficacy.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:**ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-349-900063**Report Request ID:** 18509734**Printed:** 18-Dec-23 09:02

Page 1 of 1